Our new site
My Healing Community - Home
Ctrlk
Private FB GroupHome Page
For the complete documentation index, see llms.txt. This page is also available as Markdown.

ER-Positive / HER2-Negative

Estrogen-receptor-positive/HER2-negative breast cancer research summaries that need their own treatment and resistance contexts.

This is the home page for ER-positive, HER2-negative breast cancer study‑support — it assumes some basic familiarity with ER+ disease and is designed to help patients, carers, and clinicians think more deeply about dormancy, senescence, autophagy and treatment resistance.

You might want to read one a day or one a week. Be sure to use the feedback form button if your need to reach out and connect, correct or contribute.

Tip: Bookmark this page

The notes below summarise what key ER‑positive treatments do in standard language, and then add a second layer asking: What seems to happen to dormancy, senescence, and autophagy under this pressure in preclinical and clinical work? This is the layer most of us never hear about in consults, but it should be shaping how we think about our off-label drug and supplement choices, combinations and timing.

What is ER+/HER2- Dormancy, Senescence and Autophagy?

In ER‑positive, HER2‑negative disease, treatment at every stage is never hitting just one kind of cell. At any time there are at least three overlapping cancer‑cell populations: actively dividing cells, long‑lived dormant cells, and therapy‑induced senescent cells. Standard ER‑positive treatments impact all three — killing some cells, but also pushing others into survival states supported by autophagy and stress‑response pathways. Autophagy is a process that breaks down damaged parts of the cell, reuses these as fuel or building blocks, allows the cell to survives stress instead of dying. This hub holds a growing number of research summaries that look at common ER‑positive therapies through the dormancy/senescence/autophagy lens. Understanding how standard of care therapies impact the cells that don't die is leading scientists to explore how to turn those “hiding places” into therapeutic targets.

Three overlapping cell populations in ER+ metastatic disease

In ER‑positive metastatic disease, treatment is never hitting just one kind of cell. At any time there are at least three overlapping cancer‑cell populations: actively dividing cells, long‑lived dormant cells, and therapy‑induced senescent cells

Over years of treatment, standard ER‑positive therapies don’t just kill cancer cells or turn estrogen signalling up or down; they also shape which cells survive and how they survive. Some cells are killed outright, but others slip into long‑lived dormant states or senescent‑like arrest, often supported by stress‑response pathways such as autophagy.

1. Actively dividing cells

Actively dividing cells are what endocrine therapy, CDK4/6 inhibitors and most cytotoxic drugs are designed to hit. Chemotherapy and radiation work mainly by damaging DNA or disrupting cell division, so they are most effective against cells that are actively replicating. Cells that are not dividing — dormant or senescent — largely escape these treatment pressures.

2. Dormant / quiescent cells

Dormant or quiescent cells rely heavily on autophagy for survival and are largely invisible to standard therapies. Because they are not actively dividing, chemotherapy and radiation mostly pass them by; endocrine therapy cuts their fuel supply but often does not kill them, so many simply slow their metabolism, shrink and wait. CDK4/6 inhibitors target cell‑cycle machinery that these cells barely use. They can sit in bone marrow and other protective niches for months or years, recycling their own components through autophagy until the right mix of inflammation, injury, immune disruption or niche remodelling tells them it is time to wake up.

3. Therapy‑induced senescent cells

Therapy‑induced senescent cells are not dividing, but they are held in a zombie‑like state by anti‑apoptotic proteins such as BCL‑2, BCL‑XL and BCL‑W that block the normal cell‑death signal. While they persist, they secrete SASP — an inflammatory mixture that drives chronic inflammation, immune suppression and extracellular‑matrix remodelling, and may also help nearby dormant cells tip back into growth.

Over years of treatment, standard ER‑positive therapies don’t just kill cancer cells or turn estrogen signalling up or down; they also shape which cells survive and how they survive. Some cells are eliminated, but others slip into long‑lived dormant or senescent‑like states, often supported by autophagy and other stress‑response pathways.

From a patient‑study perspective, ER‑positive breast cancer — with its long natural history and many therapies that drive dormancy and senescence — looks like a prime setting to test repurposed and off‑label drugs that target these cell survival states, especially autophagy.

Clinical trials beginning to test autophagy in ER+ breast cancer

A small but growing number of human trials are now combining autophagy‑inhibiting drugs such as chloroquine or hydroxychloroquine (HCQ) with endocrine therapy, CDK4/6 inhibitors, or chemotherapy in breast cancer, including ER‑positive disease. These early studies are asking whether blocking cytoprotective autophagy can make standard treatments more effective, especially in resistant or metastatic settings.

The first table, below is the most directly relevant ER+/HER2− metastatic trial so far that adds hydroxychloroquine to standard endocrine + CDK4/6 therapy and actually reports dose, safety and early benefit signals.

Table:

Aspect
Details

Trial title & link

Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2− metastatic breast cancer (npj Breast Cancer, 2025). URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC11770068

Setting

Human phase I, women with hormone‑receptor‑positive, HER2‑negative metastatic breast cancer, given HCQ + continuous low‑dose palbociclib + letrozole, mostly in the neoadjuvant/metastatic setting before surgery or as systemic therapy.

Who went on study (intake)

HR+/HER2− metastatic patients suitable for palbociclib + letrozole; measurable disease was not required because the primary goal was safety and dose‑finding, not classic response‑rate read‑outs.

What they actually gave

HCQ orally once daily, with continuous palbociclib 75 mg/day and letrozole 2.5 mg/day. Dose‑escalation design to find the recommended phase II HCQ dose (RP2D).

Key findings

HCQ up to 800 mg/day with continuous low‑dose palbociclib and letrozole was safe and well tolerated, and 800 mg/day HCQ was chosen as the RP2D. Some patients showed clinical benefit at 8 weeks (partial responses or clear disease control), although the trial was not powered to prove efficacy. Tumour biopsies (optional) and blood markers were used to explore autophagy/senescence signalling under this combination.

Why it matters for ER+ patients

Shows that real HR+/HER2− metastatic patients have safely received HCQ on top of palbociclib + letrozole, at a defined daily dose, with early signs that this strategy can be taken forward into larger trials aimed at hitting autophagy‑supported survival.

2. Chloroquine + taxane chemotherapy (locally advanced / metastatic, phase II)

This study isn’t ER‑only, but it is one of the clearest human examples of adding an autophagy‑blocking drug to chemotherapy in advanced breast cancer.

Table:

Aspect
Details

Trial title & link

A Phase II Study of the Efficacy and Safety of Chloroquine in Combination With Taxane or Taxane‑Like Chemotherapy in Patients With Advanced or Metastatic Breast Cancer (2020). URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC8300878

Setting

Human phase II trial in locally advanced or metastatic breast cancer (mixed subtypes, including ER+), previously treated with anthracycline‑based chemotherapy. Chloroquine was added to taxane or taxane‑like chemotherapy.

Who went on study (intake)

31 patients with advanced or metastatic breast cancer refractory to anthracycline; eligible for docetaxel, paclitaxel, nab‑paclitaxel or ixabepilone. ER status varied but included ER‑positive patients.

What they actually gave

Chloroquine 250 mg/day orally, started with and continued during taxane or taxane‑like chemotherapy (standard dosing of the taxane agent).

Key findings

Overall response rate (CR + PR) was 45%, significantly higher than the 30% expected with taxane alone in this setting (P = 0.03). Treatment was generally well tolerated, with about 13% of patients experiencing grade ≥3 adverse events; toxicity was consistent with expected taxane effects.

Why it matters for ER+ patients

Demonstrates that adding an autophagy‑inhibiting drug (chloroquine) to chemotherapy can be safe and active in humans with advanced breast cancer, including ER‑positive cases, and supports the idea that targeting survival pathways alongside standard drugs is clinically realistic, not just theoretical.

3. HCQ + endocrine therapy in ER‑positive disease (preclinical + early human signal)

This one is mostly lab work but with clear intent toward ER+ patients and early human relevance, so we present it honestly as “preclinical with patient‑facing implications”.

Most of the HCQ + endocrine work is still preclinical, but one key 2014 study gives a clear signal that autophagy inhibition can restore tamoxifen responsiveness and was used to justify early human combinations.

Table:

Aspect
Details

Study title & link

Hydroxychloroquine inhibits autophagy to potentiate antiestrogen therapy in ER+ breast cancer (Clinical Cancer Research, 2014). URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC4073207

Setting

Preclinical plus early human‑relevant work in ER‑positive breast‑cancer models that were resistant to tamoxifen (TAM) or fulvestrant (ICI); linked conceptually to neoadjuvant/DCIS clinical work (e.g. PINC trial).

What they actually tested

Anti‑estrogen‑resistant ER+ cell lines and xenograft tumours treated with tamoxifen or fulvestrant, with and without hydroxychloroquine/chloroquine as an autophagy inhibitor.

Key findings

Tamoxifen and fulvestrant induced pro‑survival autophagy in resistant cells. Blocking autophagy with HCQ/CQ restored antiestrogen sensitivity and increased tumour cell death in resistant models. The authors explicitly highlighted this as support for combining tamoxifen with CQ/HCQ in clinical trials for ER+ in situ lesions (e.g. PINC).

Why it matters for ER+ patients

This is not a full clinical trial by itself, but it provides a strong mechanistic and preclinical basis for adding HCQ to endocrine therapy in resistant ER+ disease and directly fed into early human designs using tamoxifen + HCQ in DCIS and neoadjuvant settings. It shows that autophagy‑driven resistance can be reversed in resistant ER+ models.

4. HCQ and everolimus for dormant disseminated cells after treatment (CLEVER trial, human phase II)

This one is a true human dormancy trial: people who had already finished their standard breast‑cancer treatment but still had disseminated tumour cells in their bone marrow were given hydroxychloroquine, everolimus, or both to see if those drugs could shrink the dormant‑cell pool and reduce recurrence risk.

The CLEVER trial gives some of the clearest evidence so far that repurposed, already‑approved drugs can meaningfully reduce dormant disseminated tumour cells in humans, with estimated DTC drops of around 80% on HCQ alone, 78% on everolimus alone, and 87% on the combination compared with observation.

Table:

Aspect
Details

Trial title & link

CLEVER trial – Targeting dormant tumor cells to prevent recurrent breast cancer (randomized phase II). Paper: Targeting dormant tumor cells to prevent recurrent breast cancer (2025). URL: https://pubmed.ncbi.nlm.nih.gov/40897974/

Setting

Human randomized phase II trial in breast‑cancer survivors within 5 years of diagnosis who had no visible metastases but still had disseminated tumour cells (DTCs) detectable in bone marrow after standard therapy. Includes ER‑positive cases.

Who went on study (intake)

51 patients with stage I–III breast cancer, status‑post surgery and standard systemic/local therapy, with bone‑marrow aspirate showing ≥1 DTC per 10⁶ mononuclear cells. High‑risk features included things like node‑positivity or residual disease after neoadjuvant treatment.

Treatment arms

Participants were randomised to one of four groups: hydroxychloroquine (HCQ) alone, everolimus (EVE) alone, HCQ + EVE combination, or observation (no additional drug). Treatment was given for 12 months.

DTC reduction result (the 80/78/87% numbers)

Modelling of bone‑marrow DTC counts showed estimated reductions of about 80% with HCQ alone, 78% with EVE alone, and 87% with the HCQ + EVE combination, compared with the observation arm.

Recurrence‑free survival

At a median 42‑month follow‑up, 3‑year recurrence‑free survival was high in all active arms (around 92% for HCQ and EVE, 100% for the combination) and better in patients who cleared DTCs compared with those who did not.

Why it matters for ER+ patients

CLEVER treats dormant disseminated cells as active targets, not background noise: people who had “finished” standard therapy still received HCQ, everolimus, or both, specifically to hit DTCs. The ~80% DTC‑reduction with HCQ alone shows that repurposed drugs can directly act on dormant cells in humans, opening the door to similar strategies focused on ER‑positive minimal‑residual disease.

Standard ER+ treatments seen through the dormancy / senescence / autophagy lens

For each oncology treatment an ER+/HER2- diagnosed patient is offered, it helps to remember the layer underneath the usual description – how that drug class tends to interact with dormancy, senescence and autophagy in preclinical and clinical models.

SERMs

Tamoxifen – A selective estrogen‑receptor modulator (SERM) that blocks ER in breast tissue and is widely used across pre‑ and postmenopausal settings.

Dormancy / senescence / autophagy lens: Long‑term SERM therapy can hold ER‑positive cells in a growth‑suppressed or dormant state rather than eliminating every disseminated cell, which fits with the pattern of late recurrences after years of treatment.

Aromatase inhibitors

Exemestane, letrozole, anastrozole – Aromatase inhibitors that lower estrogen production, commonly used as first‑line or subsequent endocrine therapy in postmenopausal HR‑positive disease.

Dormancy / senescence / autophagy lens: AIs deepen estrogen deprivation and further cut proliferation, but many ER‑positive cells can persist for a decade or more in slow‑cycling or dormant states, supported by survival pathways and tissue niches rather than active estrogen signalling.

CDK4/6 inhibitors

Palbociclib, ribociclib, abemaciclib – CDK4/6 inhibitors used with endocrine therapy in HR‑positive, HER2‑negative breast cancer, with overall‑survival benefits in several settings.

Dormancy / senescence / autophagy lens: CDK4/6 inhibitors enforce G1 arrest. In ER‑positive models this can generate a senescent‑like programme and activate autophagy as a survival response, with deeper, more irreversible senescence seen when autophagy is co‑inhibited.

SERDs

Elacestrant, fulvestrant – Drugs that block and degrade the estrogen receptor, used in advanced ER‑positive, HER2‑negative disease, especially with ESR1 mutations.

Dormancy / senescence / autophagy lens: SERDs strip out ER signalling and can shrink or stabilise ER‑driven disease, but resistant clones and dormant disseminated cells can still persist, especially once ESR1 mutations or alternative growth pathways emerge.

Other targeted therapies (PI3K / mTOR)

Alpelisib, everolimus – PI3K‑alpha and mTOR inhibitors used with endocrine therapy in PIK3CA‑mutated or AI‑resistant HR‑positive, HER2‑negative advanced breast cancer.

Dormancy / senescence / autophagy lens: PI3K and mTOR inhibitors stress key survival pathways; everolimus in particular clearly induces autophagy and G1 arrest in breast‑cancer models, with autophagy acting both as a way for cells to cope and as a resistance mechanism unless it is also targeted.

The ER+ breast‑cancer hub helps me understand the research that matters most to me right now and clearly places the elephant in the room — post‑treatment dormancy — centre stage, where it belongs. Thank you Abbey for all your hard work. &#xNAN;— L.B Australia

Other pages here

These pages sit closer to symptom management, adjunctive ideas, estrogen-handling questions, and the practical edges of daily life with ER-positive disease.

ER+/HER2− Hub – Coming Soon

These topics have been explored in the FB group and Google Docs and will be updated and made accessible within this hub during May 2026.

  • Radiation Post‑First‑Line Chemo in Breast Cancer

  • Bone Mets Support Hub for ER+/HER2−

  • Oral Vitamin C and Breast Cancer

  • Intake of Collagen When Healing Breast Cancer

  • Lobular Carcinoma – Invasive Pleomorphic

  • Iodine Resources for Breast Tissue Healing

References

Dormancy, senescence, and autophagy in ER-positive breast cancer

HCQ plus endocrine therapy

HCQ plus palbociclib plus letrozole

Chloroquine plus taxane chemotherapy

  • Naffouje SA, et al. A Phase II Study of the Efficacy and Safety of Chloroquine in Combination With Taxane or Taxane-Like Chemotherapy in Patients With Advanced or Metastatic Breast Cancer. Clinical Breast Cancer. 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC8300878/

HCQ and everolimus for dormant disseminated cells

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form

This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.

© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.

PreviousSupport Threads & DocsNextNew BCL‑2 Inhibitor Trial in HR+ MBC – and Why Whack-a-Mole Still Matters

Last updated

Was this helpful?